Navigation Links
Trials begin on potent new hepatitis C drug
Date:5/14/2010

The first clinical trials have started on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.

Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation in western countries. The current treatment involves two drugs ribavirin and interferon, which has to be given as an injection. Side effects are often severe and lead to patients failing to complete the treatment.

The new drug, INX-189, is taken orally and was first prepared at the Welsh School of Pharmacy in November 2008. Laboratory tests showed it killed 90 per cent of the virus at very low (nanomolar) concentration, making it one of the most potent compounds of its kind developed to date.

US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, has now started trials in healthy volunteers to assess the compound's safety. A second trial, which would evaluate the compound's effectiveness on Hepatitis patients, may follow later this year.

Professor Chris McGuigan of the Welsh School of Pharmacy, academic lead on the project, said: "This is still a very early stage of the trials process. However, progress has been encouraging so far, going from the laboratory to human trials within 18 months. We believe that INX-189 offers the possibility of more potency against Hepatitis, more rapid action in the liver, and fewer side effects than existing treatments."


'/>"/>

Contact: Professor Chris McGuigan
McGuigan@Cardiff.ac.uk
44-292-087-4537
Cardiff University
Source:Eurekalert

Page: 1

Related medicine news :

1. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
2. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
3. Scott & White Healthcare clinical trials target lymphoma, leukemia
4. Almac's North Carolina Facility Continues Growth in Academically Based Clinical Trials
5. MedTrials Launches New Online Training Website: http://core.medtrials.com
6. Experts Urge Fixes for Clinical Trials System in Crisis
7. SWOG cancer trials network awarded over $120 million in NCI grants
8. Almac to Improve Label Approval Process in Clinical Trials
9. Childhood cancer patients enrolled in clinical trials need clearer communication about their role
10. Medical schools partner to tackle barriers to minority participation in cancer clinical trials
11. Abbreviated Trials Yield Misleading Results: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... The Spiritual Care Association (SCA) ... their valuable support to patients and their families, and their overall contribution to the ... Spiritual Care Day, SCA has sent “Thank You Chaplain” cards with hand-painted artwork to ...
(Date:5/4/2016)... ... ... A new collaboration will give more researchers access to the largest and ... leader SAS will provide researchers worldwide with data management and analytics tools to explore ... , The DCRI and SAS share the goal of greater transparency and openness in ...
(Date:5/4/2016)... ... ... Washington Wellness Center today announced its tenth anniversary of providing a complete ... as an idea to provide a holistic approach to wellness has now become a ... David Swanekamp, Chiropractic Physician , the wellness center offers a complete range of ...
(Date:5/4/2016)... ... 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge , ... tooth removal, a common dental procedure, is performed for many adolescents and young adults ... in risks of complications. By providing wisdom tooth removal surgery at their office, Dr. ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... Recognizing that ... launched health brand, Verywell, have tapped David Katz, MD, MPH, president of ... , “Our shared devotion to lifestyle medicine is especially gratifying,” said Katz. “There is ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016  It,s time for an upgrade. There are many medical recorders on the ... LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a ... class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... 4, 2016 Valeritas Holdings, Inc. ... alternative public offering (APO). This was accomplished via a ... Inc. and a private placement of approximately 5 million ... share. Under the terms of the reverse ... Holdings, Inc. will trade on the OTC Markets under ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology: